India-based life sciences company PNB Vesper has reportedly completed the Phase II clinical trials of its proprietary drug, PNB-001 (GPP-Baladol), on Covid-19 patients.
In all the initial preclinical studies, the drug has demonstrated positive results, IANS reported.
In addition, it lowered the death rate by 80%, whereas Dexamethasone, a popular drug for Covid-19, only provided a 20% death rate reduction.